Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10840) 10840
Book Review (1497) 1497
Publication (682) 682
Newsletter (473) 473
Newspaper Article (88) 88
Magazine Article (53) 53
Book Chapter (42) 42
Conference Proceeding (35) 35
Book / eBook (10) 10
Dissertation (5) 5
Trade Publication Article (5) 5
Reference (3) 3
Government Document (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8568) 8568
index medicus (7417) 7417
male (3789) 3789
female (3654) 3654
polycythemia-vera (3483) 3483
hematology (3316) 3316
middle aged (3267) 3267
aged (2736) 2736
polycythemia vera (2704) 2704
adult (2509) 2509
essential thrombocythemia (2432) 2432
polycythemia (1749) 1749
mutation (1661) 1661
oncology (1482) 1482
myeloproliferative disorders (1466) 1466
janus kinase 2 - genetics (1464) 1464
polycythemia vera - complications (1415) 1415
myelofibrosis (1223) 1223
abridged index medicus (1180) 1180
old medline (1085) 1085
polycythemia vera - blood (1041) 1041
aged, 80 and over (1040) 1040
polycythemia vera - genetics (975) 975
tyrosine kinase jak2 (966) 966
polycythemia vera - diagnosis (926) 926
myeloproliferative neoplasms (876) 876
leukemia (859) 859
myeloproliferative disorders - genetics (799) 799
polycythemia vera - drug therapy (793) 793
animals (791) 791
polycythemia vera - pathology (767) 767
polycythemia vera - therapy (739) 739
thrombosis (738) 738
jak2 (727) 727
diagnosis (685) 685
research (684) 684
risk factors (640) 640
primary myelofibrosis (638) 638
adolescent (626) 626
medicine, general & internal (615) 615
prognosis (569) 569
myeloid metaplasia (556) 556
hydroxyurea (552) 552
diagnosis, differential (549) 549
thrombocythemia, essential - genetics (530) 530
genetic aspects (529) 529
care and treatment (528) 528
primary myelofibrosis - genetics (481) 481
tumors (474) 474
disorders (473) 473
hemic and lymphatic diseases (468) 468
hematocrit (456) 456
mice (450) 450
bone marrow - pathology (448) 448
chronic myeloproliferative disorders (444) 444
analysis (409) 409
cancer (402) 402
janus kinase 2 (402) 402
retrospective studies (402) 402
disease (385) 385
hydroxyurea - therapeutic use (385) 385
myeloproliferative disorders - diagnosis (377) 377
treatment outcome (372) 372
pathology (368) 368
myeloproliferative disorders - pathology (365) 365
primary myelofibrosis - pathology (365) 365
janus kinase 2 - metabolism (362) 362
therapy (360) 360
erythropoietin (357) 357
young adult (353) 353
child (352) 352
medicine & public health (338) 338
follow-up studies (337) 337
chronic disease (335) 335
medical research (331) 331
health aspects (318) 318
jak2 v617f mutation (318) 318
thrombocythemia, essential - diagnosis (317) 317
thrombocythemia, essential - complications (316) 316
platelet count (313) 313
thrombocythemia, essential - drug therapy (312) 312
risk (311) 311
bone marrow (310) 310
antineoplastic agents - therapeutic use (300) 300
expression (298) 298
primary myelofibrosis - diagnosis (298) 298
acute myeloid-leukemia (297) 297
janus kinase 2 - antagonists & inhibitors (296) 296
idiopathic myelofibrosis (295) 295
thrombosis - etiology (295) 295
hematology, oncology and palliative medicine (290) 290
anemia (289) 289
medicine, experimental (289) 289
thrombocythemia, essential - pathology (287) 287
signal transduction (286) 286
blood (278) 278
polycythemia - diagnosis (277) 277
polycythemia vera - physiopathology (277) 277
erythropoiesis (276) 276
article (274) 274
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9399) 9399
German (485) 485
French (414) 414
Russian (303) 303
Italian (175) 175
Japanese (156) 156
Spanish (134) 134
Polish (105) 105
Hungarian (66) 66
Chinese (38) 38
Korean (36) 36
Romanian (31) 31
Czech (28) 28
Danish (24) 24
Dutch (22) 22
Portuguese (20) 20
Turkish (17) 17
Swedish (16) 16
Hebrew (9) 9
Norwegian (9) 9
Slovak (9) 9
Serbian (7) 7
Finnish (6) 6
Bulgarian (4) 4
Ukrainian (4) 4
Croatian (3) 3
Slovenian (3) 3
Afrikaans (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia
by Ramos, Pedro and Casu, Carla and Gardenghi, Sara and Breda, Laura and Crielaard, Bart J and Guy, Ella and Marongiu, Maria Franca and Gupta, Ritama and Levine, Ross L and Abdel-Wahab, Omar and Ebert, Benjamin L and Van Rooijen, Nico and Ghaffari, Saghi and Grady, Robert W and Giardina, Patricia J and Rivella, Stefano
Nature Medicine, ISSN 1078-8956, 04/2013, Volume 19, Issue 4, pp. 437 - 445
Regulation of erythropoiesis is achieved by the integration of distinct signals. Among them, macrophages are emerging as erythropoietin-complementary... 
PROGENITOR CELLS | MEDICINE, RESEARCH & EXPERIMENTAL | ERYTHROBLASTIC ISLANDS | MYELOPROLIFERATIVE DISORDERS | INEFFECTIVE ERYTHROPOIESIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | DICHLOROMETHYLENE DIPHOSPHONATE | CELL BIOLOGY | SEVERE HEMOCHROMATOSIS | STRESS ERYTHROPOIESIS | EMBRYONIC STEM-CELLS | MOUSE MODEL | TYROSINE KINASE JAK2 | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
by Vannucchi, Alessandro M and Kiladjian, Jean Jacques and Griesshammer, Martin and Masszi, Tamas and Durrant, Simon and Passamonti, Francesco and Harrison, Claire N and Pane, Fabrizio and Zachee, Pierre and Mesa, Ruben and He, Shui and Jones, Mark M and Garrett, William and Li, Jingjin and Pirron, Ulrich and Habr, Dany and Verstovsek, Srdan
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 426 - 435
Ruxolitinib, an oral inhibitor of Janus kinase (JAK) 1 and 2, was associated with hematocrit control and spleen size reduction in 21% of patients with... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA | MOLECULAR RESPONSES | HYDROXYUREA | RESISTANCE | MYELOPROLIFERATIVE NEOPLASMS | INTOLERANCE | MECHANISMS | LEUKEMIA | ESSENTIAL THROMBOCYTHEMIA | Pyrazoles - therapeutic use | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents - therapeutic use | Spleen - drug effects | Thrombocytopenia - chemically induced | Remission Induction | Blood Cell Count | Janus Kinases - antagonists & inhibitors | Organ Size - drug effects | Hydroxyurea - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Hydroxyurea - therapeutic use | Polycythemia Vera - drug therapy | Aged | Spleen - pathology | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Spleen | Thrombocytopenia | Splenomegaly | Herpes zoster | Inhibitor drugs | Hematocrit | Polycythemia vera | Hydroxyurea | Thrombosis | Patients | Side effects | Polycythemia | Janus kinase | Remission | Blood diseases | Thromboembolism | Drug therapy | Drug dosages | Nuclear magnetic resonance--NMR | Phlebotomy | Restless legs syndrome | Cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Polycythemia vera and the myeloproliferative disorders
by Berk, Paul D and Berlin, Nathaniel I., 1920 and Wasserman, Louis R
1995, ISBN 0721642136, xiii, 361
Polycythemia Vera
Book
Details down arrow
4. Full Text Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
by Marchioli, Roberto and Finazzi, Guido and Specchia, Giorgina and Cacciola, Rossella and Cavazzina, Riccardo and Cilloni, Daniela and De Stefano, Valerio and Elli, Elena and Iurlo, Alessandra and Latagliata, Roberto and Lunghi, Monia and Lunghi, Francesca and Marfisi, Rosa Maria and Musto, Pellegrino and Masciulli, Arianna and Musolino, Caterina and Cascavilla, Nicola and Quarta, Giovanni and Randi, Maria Luigia and Rapezzi, Davide and Ruggeri, Marco and Rumi, Elisa and Scortechini, Anna Rita and Santini, Simone and Scarano, Marco and Siragusa, Sergio and Spadea, Antonio and Tieghi, Alessia and Angelucci, Emanuele and Visani, Giuseppe and Vannucchi, Alessandro Maria and Barbui, Tiziano and CYTO-PV Collaborative Grp and CYTO-PV Collaborative Group
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 22 - 33
In a prospective, randomized trial, patients with polycythemia vera who had a hematocrit target of less than 45% had a significantly lower rate of... 
RECURRENT THROMBOSIS | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | RISK-FACTOR | EFFICACY | WARFARIN | PREVENTION | ESSENTIAL THROMBOCYTHEMIA | LEUKOCYTOSIS | HEMATOCRIT | Cardiovascular Diseases - etiology | Follow-Up Studies | Humans | Middle Aged | Hematocrit | Phlebotomy | Polycythemia Vera - blood | Male | Thrombosis - epidemiology | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Polycythemia Vera - therapy | Janus Kinase 2 | Polycythemia Vera - complications | Thrombosis - etiology | Cardiovascular Diseases - mortality | Female | Hydroxyurea - therapeutic use | Aged | Control | Usage | Care and treatment | Causes of | Polycythemia vera | Diagnosis | Cardiovascular diseases | Risk factors | Clinical trials | Medical treatment | Mutation | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text How I treat polycythemia vera
by Vannucchi, Alessandro M
Blood, ISSN 0006-4971, 11/2014, Volume 124, Issue 22, pp. 3212 - 3220
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm associated with JAK2 mutations (V617F or exon 12) in almost all cases. The World Health... 
PRIMARY PROLIFERATIVE POLYCYTHEMIA | JAK2 V617F | RESPONSE CRITERIA | BONE-MARROW | BUDD-CHIARI-SYNDROME | MYELOPROLIFERATIVE NEOPLASMS | EXON 12 MUTATIONS | ESSENTIAL THROMBOCYTHEMIA | PRIMARY MYELOFIBROSIS | DIAGNOSTIC-CRITERIA | HEMATOLOGY | Humans | Middle Aged | Janus Kinase 2 - genetics | Polycythemia Vera - blood | Male | Physician-Patient Relations | Polycythemia Vera - genetics | Polycythemia Vera - therapy | Polycythemia Vera - diagnosis | Erythropoietin - blood | DNA Mutational Analysis | Aged | Precision Medicine | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text How I treat polycythemia vera
by Passamonti, Francesco
Blood, ISSN 0006-4971, 07/2012, Volume 120, Issue 2, pp. 275 - 284
Polycythemia vera (PV) is a clonal disorder characterized by unwarranted production of red blood cells. In the majority of cases, PV is driven by oncogenic... 
JAK2 617V-GREATER-THAN-F MUTATION | PROGNOSTIC SCORING SYSTEM | LEUKEMIC TRANSFORMATION | CHRONIC MYELOPROLIFERATIVE DISORDERS | TYROSINE KINASE JAK2 | ESSENTIAL THROMBOCYTHEMIA | PRIMARY MYELOFIBROSIS | CONGENITAL POLYCYTHEMIA | HEMATOLOGY | ALLELE BURDEN | INTERNATIONAL WORKING GROUP | Recombinant Proteins - therapeutic use | Primary Myelofibrosis - diagnosis | Pyrazoles - therapeutic use | Prognosis | Humans | Risk Factors | Interferon-alpha - therapeutic use | Janus Kinase 2 - genetics | Phlebotomy | Primary Myelofibrosis - etiology | Male | Polycythemia Vera - genetics | Polycythemia Vera - therapy | Polycythemia Vera - diagnosis | Janus Kinases - antagonists & inhibitors | Pregnancy | Polycythemia Vera - complications | Female | Hydroxyurea - therapeutic use | Mutation | Platelet Aggregation Inhibitors - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk‐stratification, and management
by Tefferi, Ayalew and Barbui, Tiziano
American Journal of Hematology, ISSN 0361-8609, 01/2017, Volume 92, Issue 1, pp. 94 - 108
Disease overview: Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and... 
ACUTE-LEUKEMIA | JAK2(V617F) MUTATION | MYELOFIBROSIS RESEARCH | LOW-DOSE ASPIRIN | LONG-TERM SURVIVAL | MYELOPROLIFERATIVE NEOPLASMS | CALRETICULIN MUTATIONS | DEFINED ESSENTIAL THROMBOCYTHEMIA | HEMATOLOGY | INTERFERON-ALPHA THERAPY | INTERNATIONAL WORKING GROUP | Primary Myelofibrosis - mortality | Humans | Polycythemia Vera - blood | Polycythemia Vera - genetics | Primary Myelofibrosis - pathology | Thrombocythemia, Essential - genetics | Calreticulin - genetics | Aspirin - administration & dosage | Erythropoietin - blood | Thrombocytosis - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aspirin - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Thrombocytosis - pathology | Thrombocythemia, Essential - drug therapy | Primary Myelofibrosis - diagnosis | Diagnosis, Differential | Risk Assessment | Interferon-alpha - therapeutic use | Janus Kinase 2 - genetics | Hydroxyurea - administration & dosage | Thrombocythemia, Essential - blood | Polycythemia Vera - diagnosis | Thrombocytosis - diagnosis | Interferon-alpha - administration & dosage | Receptors, Thrombopoietin - genetics | Thrombocythemia, Essential - diagnosis | Hydroxyurea - therapeutic use | Polycythemia Vera - drug therapy | Mutation | Erythropoietin | Polycythemia | Leukemia | Diagnosis | Tumor proteins | Thrombosis | Risk factors | Blood clot | Pruritus | Age | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
by Scott, Mike A and Scott, Linda M and Tong, Wei and Levine, Ross L and Beer, Philip A and Stratton, Michael R and Futreal, P. Andrew and Erber, Wendy N and McMullin, Mary Frances and Harrison, Claire N and Warren, Alan J and Gilliland, D. Gary and Lodish, Harvey F and Green, Anthony R
The New England Journal of Medicine, ISSN 0028-4793, 02/2007, Volume 356, Issue 5, pp. 459 - 468
A V617F mutation in the Janus kinase 2 gene ( JAK2 ) occurs in most patients with polycythemia vera and in many with essential thrombocythemia or idiopathic... 
V617F MUTATION | MYELOFIBROSIS | MEDICINE, GENERAL & INTERNAL | ACTIVATING MUTATION | MYELOPROLIFERATIVE-DISORDERS | DISEASE | TYROSINE KINASE JAK2 | ESSENTIAL THROMBOCYTHEMIA | DIAGNOSTIC-CRITERIA | JAK2V617F | MYELOID METAPLASIA | Phosphotransferases - metabolism | Polycythemia - genetics | Phosphorylation | Signal Transduction | Exons | Humans | Janus Kinase 2 - genetics | Molecular Sequence Data | Polycythemia Vera - genetics | Animals | Base Sequence | Janus Kinase 2 - metabolism | Bone Marrow Transplantation | Heterozygote | Mice | Mice, Inbred BALB C | Mutation | Disease Models, Animal | Genetic aspects | Research | Gene mutations | Polycythemia | Myeloproliferative disorders | Bone marrow | Blood diseases | Genes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Spinal cord infarction during physical exertion due to polycythemia vera and aortoiliac occlusive disease: A case report
by Lin, Wei-Pin and Kuan, Ta-Shen and Lin, Cho-I and Hsu, Lin-Chieh and Lin, Yu-Ching
Medicine, ISSN 0025-7974, 08/2018, Volume 97, Issue 35, pp. e12181 - e12181
Rationale: Spinal cord infarction is rarely caused by hypercoagulable states. Polycythemia vera (PV) is a myeloproliferative neoplasm that can contribute to... 
spinal cord injury | MEDICINE, GENERAL & INTERNAL | polycythemia vera | spinal cord ischemia | physical exertion | aortoiliac occlusive disease | ISCHEMIC-STROKE | Infarction - etiology | Physical Exertion - physiology | Humans | Middle Aged | Male | Spinal Cord - blood supply | Polycythemia Vera - complications | Aortic Diseases - physiopathology | Aortic Diseases - complications | Aorta - physiopathology | Arterial Occlusive Diseases - complications | Arterial Occlusive Diseases - physiopathology | Iliac Artery - physiopathology | Polycythemia Vera - physiopathology | Spinal cord injuries | Exercise | Health aspects | Thrombosis | Risk factors | Blood clot | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Progression of primary myelofibrosis to polycythemia vera A case report
by Guo, Y and Xu, WW and Dong, L and Huang, N and Bi, KH
MEDICINE, ISSN 0025-7974, 07/2017, Volume 96, Issue 28, pp. e7464 - e7464
Rationale: This case report describes the progression of primary myelofibrosis (PMF) to polycythemia vera (PV), and discuss its potential mechanisms. Patient... 
myeloproliferative neoplasms | TRANSFORMATION | DIAGNOSIS | primary myelofibrosis | progression | CLASSIFICATION | ESSENTIAL THROMBOCYTHEMIA | INTERNATIONAL WORKING GROUP | POLYCYTHAEMIA/ERYTHROCYTOSIS | MEDICINE, GENERAL & INTERNAL | polycythemia vera | DYNAMIC PROGNOSTIC MODEL | MYELOID METAPLASIA | PREDICT SURVIVAL | Primary Myelofibrosis - diagnosis | Primary Myelofibrosis - drug therapy | Primary Myelofibrosis - genetics | Humans | Middle Aged | Primary Myelofibrosis - physiopathology | Female | Polycythemia Vera - drug therapy | Polycythemia Vera - genetics | Polycythemia Vera - diagnosis | Disease Progression | Polycythemia Vera - physiopathology | Myelofibrosis | Stem cells | Development and progression | Polycythemia vera | Diagnosis | Research | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera A Case Report
by Iurlo, A and Dagna, L and Cattaneo, D and Orofino, N and Bianchi, P and Cavalli, G and Doglioni, C and Gianelli, U and Cortelezzi, A
MEDICINE, ISSN 0025-7974, 05/2016, Volume 95, Issue 20, pp. e3697 - e3697
Erdheim-Chester disease is a rare form of non-Langerhans cell histiocytosis characterized by the migration and infiltration of lipidladen CD68(+), CD1a(-) and... 
DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | THERAPY | EFFICACY | PROGNOSIS | CONSENSUS | MUTATIONS | JAK2 | VEMURAFENIB | Erdheim-Chester Disease - diagnostic imaging | Humans | Janus Kinase 2 - genetics | Polycythemia Vera - diagnostic imaging | Male | Tomography, X-Ray Computed | Kidney Diseases - diagnostic imaging | Positron-Emission Tomography | Erdheim-Chester Disease - pathology | Polycythemia Vera - complications | Heart Diseases - etiology | Proto-Oncogene Proteins B-raf - genetics | Bone Marrow - pathology | Erdheim-Chester Disease - complications | Ultrasonography | Aged | Heart Diseases - diagnostic imaging | Kidney Diseases - etiology | Polycythemia Vera - pathology | CT imaging | Usage | Research | Diagnosis | Macrophages | Langerhans-cell histiocytosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Apparent ‘JAK2‐negative’ polycythaemia vera due to compound mutations in exon 14
by Tiong, Ing Soo and Casolari, Debora A and Moore, Sarah and Nguyen, Tran and Van Velzen, Merel J. M and Zantomio, Daniela and Scott, Hamish S and D'Andrea, Richard J and Hahn, Christopher N and Ross, David M
British Journal of Haematology, ISSN 0007-1048, 07/2017, Volume 178, Issue 2, pp. 333 - 336
myeloproliferative neoplasms | JAK | polycythaemia vera | next generation sequencing | compound mutation | JAK2 | DIAGNOSIS | HEMATOLOGY | Exons | Humans | Middle Aged | Janus Kinase 2 - genetics | Erythrocyte Indices | Genotype | Male | Polycythemia Vera - genetics | Polycythemia Vera - diagnosis | DNA Mutational Analysis | Bone Marrow - pathology | Alleles | Aged, 80 and over | Adult | Female | Aged | Mutation | Amino Acid Substitution | Janus kinase 2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Thromboembolic events in polycythemia vera
by Griesshammer, Martin and Kiladjian, Jean-Jacques and Besses, Carlos
Annals of Hematology, ISSN 0939-5555, 5/2019, Volume 98, Issue 5, pp. 1071 - 1082
Thromboembolic events and cardiovascular disease are the most prevalent complications in patients with polycythemia vera (PV) compared with other... 
Thromboembolic events | Medicine & Public Health | Hematology | Oncology | Polycythemia vera | Interferon | Thrombosis | JAK inhibitors | HYDROXYUREA | MYELOPROLIFERATIVE NEOPLASMS | ESSENTIAL THROMBOCYTHEMIA | PROGNOSTIC VALUE | SPLANCHNIC VEIN-THROMBOSIS | LOW TOXICITY | BENEFIT-RISK PROFILE | THERAPY | LOW-DOSE ASPIRIN | VENOUS THROMBOEMBOLISM | HEMATOLOGY | Pyrazoles - therapeutic use | Age Factors | Humans | Risk Factors | Phlebotomy | Anticoagulants - therapeutic use | Interferons - therapeutic use | Polycythemia Vera - therapy | Thromboembolism - etiology | Polycythemia Vera - diagnosis | Thromboembolism - therapy | Thromboembolism - diagnosis | Polycythemia Vera - complications | Hydroxyurea - adverse effects | Thrombosis - etiology | Hydroxyurea - therapeutic use | Aspirin - therapeutic use | Thrombosis - therapy | Thrombosis - diagnosis | Aspirin | Polycythemia | Mortality | Palliative treatment | Anticoagulants (Medicine) | Biological response modifiers | Thromboembolism | Health aspects | Risk factors | Health risk assessment | Index Medicus | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights